The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Commentary|Videos|June 19, 2024
Cancer Hijacks Your Bone Marrow and Your Immune System: What Are You Going to Do About It?
Author(s)Thomas Marron, MD, PhD
Thomas Marron, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, discusses the ways cancer attacks the bone marrow and immune system.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
3
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5